Abstract Body

SARS-CoV-2 infects the host by binding of its spike receptor binding domain (S RBD) to angiotensin converting enzyme 2 (ACE2) on the surface of cells in the respiratory tract and gut; thus therapeutics that prevent this interaction are of interest because they have the potential to inhibit propagation of infection. A recombinant ‘ACE2 Decoy’ that competitively binds S RBD and neutralizes SARS-CoV-2 infection represents such a therapeutic approach. The impact of S RBD mutations found in the rapidly spreading UK, South African, and California SARS-CoV-2 variants on ACE2 Decoy affinity is an important factor in design. Here, we identified a high-affinity SARS-CoV-2-neutralizing ACE2 Decoy that maintains its high affinity against RBD with mutations found in emerging variants.

We used Molecular Dynamic (MD) simulation of S RBD-ACE2 interactions to predict ACE2 residues that if mutated, might increase affinity for S RBD and thus successfully compete with endogenous ACE2 for binding. Recombinant ACE2-IgG1Fc and -IgAFc fusion proteins expressing mutations predicted to increase S RBD binding affinity were produced, purified, and screened for binding affinities against wild type S RBD and S RBD expressing E484K, K417N, N501Y, or L452R alone and in combinations of: K417N/N501Y; E484K/N501Y; K417N/E484K; and K417N/E484K/N501Y (found in the South African variant). The ability of the Decoy with the highest affinity to neutralize SARS-CoV-2 infection was determined by a live virus assay using Vero E6 cells. An additional mutation (H374N) to inhibit enzymatic activity of ACE2 was added to the Decoy with the highest affinity from mutation screening.

Eleven of the ACE2 mutations predicted to increase affinity for S RBD were tested, revealing the ACE2 Decoy with T27Y and H34A mutations to have the highest S RBD affinity and the ability to neutralize SARS-CoV-2 infection of cells. Both the ACE2 wild type (WT)-IgG1Fc and the ACE2(T27Y/H34A/H374N)-IgG1Fc Decoys showed enhanced binding affinity for S RBD with either N501Y and L452R mutations alone. Interestingly, the South African variant K417N mutation alone decreased affinity, but not in combination with the N501Y mutation.

The potential efficacy of the ACE2 (T27Y/H34A/H374N)-IgG1FC Decoy is not decreased by the UK, South African, or California variant mutations and will undergo testing in animal models likely by expression using a human adenovirus (hAd5) construct to enhance stability.